Navigation Links
Leading global Big Pharma companies of 2005

I always look forward to writing this particular article with great anticipation! Why, you say? It is part of an annual ritual that I have followed with eagerness as I grew up in the pharmaceutical industry, initiating in my 10 years at Pfizer (way before Pfizer was the juggernaut it is today). At Pfizer, we were all anxious to see the annual company ranking results ......

Full article >>> an old friend and colleague who was retiring from Pfizer the week that I was there, after 31 years with the company. In fact, he and I started at Pfizer the same year (wow, I was really feeling old).

As I toured Pfizer Brazil's offices, we were reminiscing of the old days when Pfizer's offices in most Latin American countries were usually located 45 minutes to an hour from city centers a......

Full article >>> >N/ARoche* (Swiss + Chugai)$15.7N/A99Wyeth (U.S.)$15.3+10%108Bristol-Myers Squibb$15.3<1%>1111Eli Lilly (U.S.)$14.7+12%1210Abbott Labs (U.S.)$14.0+16%
Full article >>> les from acquisition of Japanese company Chugai but does not include sales from majority-owned position in Genentech
** merger of Yamanouchi and Fujisawa to become Astellas
*** does not include recently-announced acquisition of Schering AG
**** merger in September, 2005 of Daiichi and Sankyo

By the way, as a manner of comparison, let's take a look at the rankings of the pharm......

Full article >>> re within the top 30 companies, Amgen and Genentech, with Amgen close to breaking into the top 10 companies although its growth is slowing down; Genentech continues to move up in the ranks and actually finished the year with a market cap higher than Amgen's - approaching $100 billion
  • The Japanese companies continue to globalize due to the weakness of their own home market and inc......

    Full article >>> 6Novartis$4.518.0%7Roche (includes Chugai)$4.226.8%8Merck$3.817.3%9Eli Lilly$3.020.4%10Amgen$2.319.2%11Schering-Plough$1.925.0%
    Full article >>> >Abbott Labs at about 13% of sales is on the low side while Eli Lilly is aggressively investing (20% of sales); Baxter, at about 17% of sales, is just slightly above the average for the industry.

    Note that, on average, 50% of a Big Pharma's R&D budget is being spent on the development of in-licensed drugs (from smaller companies), with some companies spend......

    Full article >>> altimore, Chicago, Cleveland, and Denver. Rosen is also a founder and board member of the Illinois Biotechnology Industry Organization. He can be reached at

  • The opinions expressed herein or statements made in the above column are solely those of the author and do not necessarily reflect th......

    Full article >>>
    '"/> By Michael Rosen 05/09/06

    Related biology technology :

    1. Leading cancer institute to install three TomoTherapy systems
    2. The state of global biotech: An Ernst & Young perspective
    3. Doyle announces new energy, global warming policies
    4. Lucigen Corp. enters global licensing agreement
    5. Work-life imbalance - A global problem getting worse
    6. Learning to swim in the global talent pool
    7. Federal and global guidelines on stem cell research offer a level playing field
    8. Wisconsin plant is part of NCRs global RFID initiative
    9. Whither Wisconsin manufacturing in the new global economy?
    10. In the wake of Katrina, more questions than answers about global climate change
    11. Is America prepared to win the global skills race?
    Post Your Comments:

    (Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
    (Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
    (Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
    (Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
    Breaking Biology Technology:
    (Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
    (Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
    (Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
    Breaking Biology News(10 mins):